The new custom sensors will allow for passively recording compliance data, better informing patients and their physicians of adherence and other factors.
The system is designed to deliver more objective measurements, while also enabling patients to perform these tests from their homes.
Under the deal, Novartis will use Qualcomm Life's connectivity solutions to power its next-gen connected Breezhaler, the inhaler for its COPD portfolio.
ViaOpta Nav and ViaOpta Daily help visually impaired people walk to a nearby cafe, go to the pharmacy, and pick up their grandchildren at the kindergarten.
The application includes education, monitoring tools and gamification components to keep patients engaged and improve the patient-physician dialogue.
The chip maker's VC arm, Qualcomm Ventures, will be working with Novartis' health experts to target early stage companies and support select tech innovations.
Novartis will rely on the 2net technology to digitize its clinical trials, while Novartis will use it to support its Balance Rewards for healthy choices program.
The technology offers potential to transform eye care, but there's a long road ahead before we see the smart lens hitting a pharmacy near you.